Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience.

Mohammed S, Aljundi AH, Kasem M, Alhashemi M, El-Menyar A.

J Adv Pharm Technol Res. 2017 Jan-Mar;8(1):14-18. doi: 10.4103/2231-4040.197370.

2.

Oral anticoagulation with vitamin K inhibitors and determinants of successful self-management in primary care.

Tamayo Aguirre E, Galo-Anza A, Dorronsoro-Barandiaran O, Del Burgo EU, Ostiza Irigoyen A, Garcia-Carro A, Lopez-Fernandez I, Colera N, Saez-Garbayo P, Tamayo-Uria I.

BMC Cardiovasc Disord. 2016 Sep 13;16(1):180. doi: 10.1186/s12872-016-0326-z.

3.

Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system.

Lin SW, Kang WY, Lin DT, Lee J, Wu FL, Chen CL, Tseng YJ.

BMC Med Genomics. 2014;7 Suppl 1:S13. doi: 10.1186/1755-8794-7-S1-S13. Epub 2014 May 8.

4.

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Köhler C, Werth S, Sahin K, Tittl L, Hänsel U, Weiss N.

Blood. 2014 Aug 7;124(6):955-62. doi: 10.1182/blood-2014-03-563577. Epub 2014 May 23.

5.

Prevention and treatment of venous thromboembolism in patients with cancer.

Hogg K, Carrier M.

Ther Adv Hematol. 2012 Feb;3(1):45-58. doi: 10.1177/2040620711422590.

6.
7.

Predicting the risk of venous thromboembolism recurrence.

Heit JA.

Am J Hematol. 2012 May;87 Suppl 1:S63-7. doi: 10.1002/ajh.23128. Epub 2012 Feb 24. Review.

8.

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G.

Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292. Review.

9.

Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.

Chen WT, White CM, Phung OJ, Kluger J, Ashaye AO, Sobieraj DM, Makanji S, Tongbram V, Baker WL, Coleman CI.

Mayo Clin Proc. 2011 Jun;86(6):509-21. doi: 10.4065/mcp.2010.0755. Review.

10.

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.

Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H.

Br J Cancer. 2011 Feb 1;104(3):413-8. doi: 10.1038/sj.bjc.6606074. Epub 2011 Jan 18.

11.

Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, Heit JA.

Mayo Clin Proc. 2009 Dec;84(12):1079-94. doi: 10.4065/mcp.2009.0278. Review.

12.

Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics.

Cruess DG, Localio AR, Platt AB, Brensinger CM, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Kimmel SE.

Int J Behav Med. 2010 Mar;17(1):33-42. doi: 10.1007/s12529-009-9052-6.

13.

Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study.

Spencer FA, Gore JM, Reed G, Lessard D, Pacifico L, Emery C, Crowther MA, Goldberg RJ.

Thromb Haemost. 2009 May;101(5):878-85.

14.

Effect of an interactive voice response system on oral anticoagulant management.

Oake N, van Walraven C, Rodger MA, Forster AJ.

CMAJ. 2009 Apr 28;180(9):927-33. doi: 10.1503/cmaj.081659.

15.

Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial.

Holbrook A, Labiris R, Goldsmith CH, Ota K, Harb S, Sebaldt RJ.

CMAJ. 2007 May 22;176(11):1583-7.

16.

Effectiveness of warfarin among patients with cancer.

Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM.

J Gen Intern Med. 2007 Jul;22(7):997-1002. Epub 2007 May 3.

17.

Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin.

Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH.

J Gen Intern Med. 2005 Dec;20(12):1114-9.

18.

Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial.

Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR.

CMAJ. 2003 Aug 19;169(4):293-8. Erratum in: CMAJ. 2004 Feb 17;170(4):451.

19.

American College of Medical Genetics consensus statement on factor V Leiden mutation testing.

Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. Leiden Working Group.

Genet Med. 2001 Mar-Apr;3(2):139-48. No abstract available.

20.

Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy.

Man-Son-Hing M, Laupacis A, O'Connor AM, Hart RG, Feldman G, Blackshear JL, Anderson DC.

J Gen Intern Med. 2000 Oct;15(10):723-30.

Supplemental Content

Support Center